Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
- Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect)
- , Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD)
- , COVID-19 Global Rheumatology Alliance
- University of California,San Diego
- The University of North Carolina at Chapel Hill
- Guy's & St Thomas' NHS Foundation Trust
- King's College London
- Icahn School of Medicine at Mount Sinai
- Deutsche Rheuma-Forschungszentrum Berlin
- Instituto de Salud Musculoesquelética (INMUSC)
- Portuguese League Against Rheumatic Diseases
- Goteborgs Universitet University of Gothenburg
- University of Campania "Luigi Vanvitelli"
- Humanitas IRCCS Research Hospital
- Santa Maria University Hospital
- Centro Hospitalar do Baixo Vouga
- Justus-Liebig University
- Jena University Hospital
- University Hospital Heidelberg
- German Society for Rheumatology
- Rheumatology Department
- University of Southern California
- Mayo Clinic
- Argentine Society of Rheumatology
- Brigham and Womens Hospital
- Harvard Medical School
- Universidade Federal do Rio Grande do Sul
- Federal University of Pernambuco
- Universidade Federal de Minas Gerais
- University of Lille I (Universite des Sciences et Techniques de Lille Flandres Artois)
- Créteil Université Paris Est
- University Hospital of Toulouse
- Hospital Italiano de Buenos Aires
Research output: Contribution to journal › Article › peer-review